• Resolute Onyx™ DES Meets Primary Endpoint in First-Ever Clinical Study Comparing Drug-Eluting Stents in High-Bleeding Risk (HBR) Patients with One-Month DAPT

    Source: Nasdaq GlobeNewswire / 26 Sep 2019 10:50:00   America/Los_Angeles

    N/A
Share on,